Harpreet S. Dhaliwal - 26 Feb 2026 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Signature
Harpreet S. Dhaliwal, by /s/ Peter N. Efremenko, Attorney-In-Fact
Issuer symbol
PCVX
Transactions as of
26 Feb 2026
Net transactions value
-$46,919
Form type
4
Filing time
02 Mar 2026, 20:07:08 UTC
Previous filing
02 Jan 2026
Next filing
11 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dhaliwal Harpreet S. Chief Technical Ops Officer C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS Harpreet S. Dhaliwal, by /s/ Peter N. Efremenko, Attorney-In-Fact 02 Mar 2026 0001886794

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Award $0 +53,409 +223% $0.000000 77,337 26 Feb 2026 Direct F1
transaction PCVX Common Stock Tax liability $18,098 -292 -0.38% $61.98 77,045 28 Feb 2026 Direct F2
transaction PCVX Common Stock Tax liability $28,821 -465 -0.6% $61.98 76,580 02 Mar 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Award $0 +46,424 $0.000000 46,424 26 Feb 2026 Common Stock 46,424 $60.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2 Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F3 1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.